IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
IceCure Medical Ltd. - Ordinary Shares (ICCM)
Company Research
Source: PR Newswire
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors =3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study populationFull analysis of results to be presented at European Conference of Interventional Oncology 2026 in Basel, SwitzerlandData supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets where it is approved for kidney cancer, including the U.S. and Europe CAESAREA, Israel, March 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced positive top-line results from its ICESECRET clinical trial of ProSense® for the treatment of small renal masses ("SRMs") in kidney cancer patients.A total of 114 patients were enrolled in the study, of whom 112 were evaluated at a m
Show less
Read more
Impact Snapshot
Event Time:
ICCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCM alerts
High impacting IceCure Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ICCM
News
- IceCure Appoints Meir Peleg as Chief Financial OfficerPR Newswire
- Icecure Medical Ltd (ICCM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic U.S. ... [Yahoo! Finance]Yahoo! Finance
- IceCure Medical (ICCM) Q4 2025 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- IceCure Reports 2025 Full Year Financial & Operational Results [Yahoo! Finance]Yahoo! Finance
ICCM
Earnings
- 3/17/26 - Beat
ICCM
Sec Filings
- 3/25/26 - Form 6-K
- 3/25/26 - Form EFFECT
- 3/24/26 - Form 6-K
- ICCM's page on the SEC website